Fig. 1

Nintedanib in combination with paclitaxel (PTX) delays tumor growth in LM2–4 primary tumors. a) Antitumor effect of nintedanib alone and when combined with PTX in the LM2–4 orthotopic primary tumor model. Nintedanib alone showed a very modest antitumor effect. Combination treatment resulted in the greatest inhibition of primary tumor growth. Treatments started after 14 days of cell implantation. Data are presented as means ± SD, n = 5. Statistical analysis on day 40 after cell implantation. ANOVA followed by Tukey’s Multiple Comparison Test, *** p < 0.001. b) Prior published results showing, in contrast, sunitinib having anti-tumor effect in this model, which was not improved by combination with PTX. Modified from Guerin et al., 2013 [74]